Search

Displaying results 3731 - 3740 of 5898 in total
  1. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.

  2. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders. … It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha.

  3. Drug

    VP025

    go.drugbank.com/drugs/DB05133
    Experimental

    It is considered to be a systemic anti-inflammatory and neuroprotective agent. … It also shows the ability to reduce inflammation across the blood-brain barrier and improve correlates of memory and learning function.

  4. Drug

    Mersalyl

    go.drugbank.com/drugs/DB09338
    Experimental

    Interestingly, it has been found to have antiviral properties in mice [L1584]. … The sodium salt of a mercury-containing derivative of salicylamide, was formerly used (often in combination with theophylline) to treat edema, due to its powerful diuretic properties [L1577].

  5. Drug

    Calusterone

    go.drugbank.com/drugs/DB01564
    ExperimentalIllicit

    A 17-alkylated orally active androgenic steroid. A Schedule IV drug in Canada.

    Synonyms: 17beta-Hydroxy-7beta,17-dimethylandrost-4-en-3-one, 17-beta-Hydroxy-7-beta,17-alpha-dimethylandrost-4-ene-3-one
  6. Drug

    Myrcludex B

    go.drugbank.com/drugs/DB14853
    Investigational

    With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D). … Myrcludex B is under investigation in clinical trial NCT03546621 (A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination

  7. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    Encorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP...

  8. Drug

    Seletracetam

    go.drugbank.com/drugs/DB05885
    Investigational

    Seletracetam is a pyrrolidone derivative and with a structural similarity to newer generation antiepileptic drug levetiracetam. … As of 2010, its production was further halted due to the investigation of a newer antiepileptic agent, brivaracetam.

  9. Drug

    STI-1499

    go.drugbank.com/drugs/DB16487
    Investigational

    STI-1499 (COVI-GUARD was under investigation in clinical trial NCT04454398 to evaluate its safety and efficacy in patients with moderate COVID-19.

  10. Drug

    PTI-801

    go.drugbank.com/drugs/DB05300
    Investigational

    PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone.